Strategic partnerships Novilytic has established collaborations with Purdue Research Foundation and is recognized as a BTI 2025 finalist, indicating active interest from research institutions and potential for co-development or licensing opportunities that can expand market access.

Clinical and pharma relevance The Proteometer platform targets protein purification simplification and analysis critical to biopharma workflows, suggesting strong fit for contract labs, drug development groups, and life science companies seeking efficiency gains and reduced labor costs.

Funding momentum Past NIH SBIR support and a seed round combined with a current revenue level imply financial stability and credibility for customer demonstrations, partnerships, and expansion into higher-margin product offerings.

Product-led efficiency Consolidating multi-instrument processes into a single kit with titer and variant analysis positions Novilytic as a compelling value proposition for labs prioritizing throughput, quality control, and cleaner workflows.

Market readiness A relatively small team with a clear product suite and existing revenue suggests target buyer segments include mid-size biotech and contract research organizations that can benefit from scalable, cost-effective protein analytics.